Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier dysfunction in an experimental murine model of human African trypanosomiasis by Rodgers, Jean et al.
Accepted Manuscript
Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier
dysfunction in an experimental murine model of human African trypanosomia-
sis
Jean Rodgers, Barbara Bradley, Peter G.E. Kennedy
PII: S1046-2023(16)30405-4
DOI: http://dx.doi.org/10.1016/j.ymeth.2017.06.015
Reference: YMETH 4245
To appear in: Methods
Received Date: 28 February 2017
Revised Date: 8 June 2017
Accepted Date: 16 June 2017
Please cite this article as: J. Rodgers, B. Bradley, P.G.E. Kennedy, Delineating neuroinflammation, parasite CNS
invasion, and blood-brain barrier dysfunction in an experimental murine model of human African trypanosomiasis,
Methods (2017), doi: http://dx.doi.org/10.1016/j.ymeth.2017.06.015
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier 
dysfunction in an experimental murine model of human African trypanosomiasis 
Jean Rodgersa,*, Barbara Bradleya, Peter G.E. Kennedyb   
a Institute of Biodiversity, Animal Health & Comparative Medicine, College of Medical, 
Veterinary & Life Sciences, University of Glasgow, Glasgow, G61 1QH, UK 
b
 Institute of Infection, Inflammation and Immunity, College of Medical, Veterinary & Life 
Sciences, University of Glasgow, Glasgow, G61 1QH, UK
 
* Corresponding author:  Jean.Rodgers@glasgow.ac.uk 
  
  
Abstract 
Although Trypanosoma brucei spp. was first detected by Aldo Castellani in CSF samples 
taken from sleeping sickness patients over a century ago there is still a great deal of debate 
surrounding the timing, route and effects of transmigration of the parasite from the blood to 
the CNS.  In this investigation, we have applied contrast-enhance magnetic resonance 
imaging (MRI) to study the effects of trypanosome infection on the blood-brain barrier (BBB) 
in the well-established GVR35 mouse model of sleeping sickness.  In addition, we have 
measured the trypanosome load present in the brain using quantitative Taqman PCR and 
assessed the severity of the neuroinflammatory reaction at specific time points over the 
course of the infection.   
Contrast enhanced – MRI detected a significant degree of BBB impairment in mice at 14 
days following trypanosome infection, which increased in a step-wise fashion as the disease 
progressed.  Parasite DNA was present in the brain tissue on day 7 after infection.  This 
increased significantly in quantity by day 14 post-infection and continued to rise as the 
infection advanced.  A progressive increase in neuroinflammation was detected following 
trypanosome infection, reaching a significant level of severity on day 14 post-infection and 
rising further at later time-points.  In this model stage-2 disease presents at 21 days post-
infection. 
The combination of the three methodologies indicates that changes in the CNS become 
apparent prior to the onset of established stage-2 disease.  This could in part account for the 
difficulties associated with defining specific criteria to distinguish stage-1 and stage-2 
infections and highlights the need for improved staging diagnostics. 
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1 Introduction 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by 
infection with the parasitic protozoans Trypanosoma brucei gambiense (T.b.gambiense) or 
Trypanosoma brucei rhodesiense (T.b.rhodesiense) and is spread by the bite of the tsetse 
fly insect vector [1].  The disease is usually fatal if not diagnosed and treated with 
appropriate chemotherapy.  T.b.gambiense is by far the more prevalent of the two infections 
and is responsible for approximately 97% of all reported cases with T.b.rhodesiense 
accounting for the remaining 3%.  The parasites are restricted to sub-Saharan Africa where 
approximately 70 million people are at risk of infection.  However, following the application of 
effective control and surveillance strategies the number of reported new cases fell to less 
than 10,000 in 2009 and has continued to decline with less than 3,000 new cases recorded 
in 2015 [2].  These figures suggest that elimination of the disease, defined as less than one 
case per 10,000 population in at least 90% of endemic areas, by 2020 is an achievable 
target.  Nevertheless, the reported case number likely depicts a significant under 
representation of the scale of the problem and WHO estimate that the actual case number is 
closer to 20,000 [1].  Re-emergence of the disease to epidemic levels has occurred 
historically [3] and this recurrence emphasises the necessity to sustain current control 
strategies.   
Following infection the disease progresses through two stages.  During stage-1 the parasites 
proliferate in the blood, lymphatic system and peripheral organs.  However, the most serious 
form of HAT, stage-2, occurs when the trypanosomes circumvent the blood-brain barrier 
(BBB) to enter and establish within the CNS.  Gambiense infections are associated with a 
chronic progressive course and can take months to years before stage-2 disease is reached, 
while rhodesiense infections are more acute with parasites entering the CNS within a matter 
of weeks [4].  The progression of the infection to the CNS-stage is associated with the 
development of a neuroinflammatory reaction described in only a limited number of human 
cases [5, 6].  This neuroinflammatory response to trypanosome infection has been mirrored 
in both rodent and primate models of the human disease and is characterised by 
inflammatory cells, including lymphocytes, macrophages and plasma cells, infiltrating the 
meninges and choroid, followed by inflammation of the parenchymal vessels and lastly the 
development of encephalitis.  Astrocyte and microglial cell activation accompany this 
response although little neuronal damage or demyelination occur until the terminal stages of 
the disease are reached [5, 7-9].   
The precise microenvironment required within the brain to conserve optimal function is 
maintained by the presence of specialised barriers situated between the neural tissue and 
the circulating blood [10].  These barriers protect the brain from the vast majority of toxins 
  
and pathogens as well as regulate the exchange of nutrients, metabolites, molecules and 
ions between the brain parenchyma and the blood by means of specific transporters and ion 
channels [11].  The most extensive barrier type is found between the blood and the brain 
parenchyma and is formed through a complex functional interplay between brain 
microvascular endothelial cells, which are bound together by sophisticated ‘tight junctions’, 
pericytes, astrocytes, neurons and microglial cells.  Together these cells constitute the 
neurovascular units that comprise the ‘classical’ parenchymal BBB [11].  There are 
additional barriers in the choroid plexus separating the blood from the ventricular CSF, and 
between the blood and subarachnoid CSF. These barriers have endothelial cells joined by 
tight junctions but lack the other cellular components of the parenchymal BBB [12].   
Numerous neurological conditions, of both infectious and non-infectious aetiology, can 
initiate various degrees of BBB impairment [13-15].  However, the impact of trypanosome 
infection on BBB function remains controversial [16-19].  Rhodamine dye, injected into the 
jugular vein of rats during the advanced stages of T.b.brucei infection, has been found 
permeating the brain cortical white and grey matter, indicating the presence of BBB 
dysfunction in these animals [17].  In a similar rat model, Mulenga et al. [16] detected 
increasing numbers of parasites in the brain parenchyma as the infection progressed, 
though no changes were seen in the staining patterns of the tight junction proteins occludin 
and zonula occludens 1, or the penetration of fibrinogen or IgG.  In this instance, the findings 
suggest that trypanosome infection and transmigration into the CNS does not result in loss 
of BBB integrity.  The application of an in vitro BBB model utilising human brain 
microvascular endothelial cells has provided further evidence suggesting that trypanosomes 
do not cause lasting damage to the BBB [19].  This study showed that T.b.rhodesiense 
induced only a transient reduction in transendothelial electrical resistance (TEER), which 
was most pronounced around 3 hours following introduction of the parasites [19].   
More recent studies, employing contrast-enhanced magnetic resonance imaging (CE-MRI) 
to investigate BBB function in a murine model of HAT, demonstrated significant and 
widespread BBB dysfunction during CNS-stage disease [20].  Furthermore, the barrier 
impairment was present in animals displaying only mild to moderate neuroinflammatory 
changes in the brain; typically comprised of inflammatory cells in the meninges and the 
development of perivascular cuffs around some of the blood vessels.  In the investigation 
presented here we have extended these findings to ascertain when BBB impairment 
becomes apparent following T.b.brucei infection and measured the severity of the 
dysfunction.  In addition, the degree of neuroinflammation and the trypanosome burden in 
the brain has been determined during the progression of the disease.   
 
  
2 Materials and methods 
2.1 Animals and infections 
All animal experiments were approved by the University of Glasgow Ethical Review 
Committee and performed in accordance with the ARRIVE guidelines, UK Animals (Scientific 
Procedures) Act, 1986 and EU directive 2010/63/EU. 
The well-established Trypanosoma brucei (T.b.) brucei GVR35 mouse model of human 
African trypanosomiasis was used throughout this study.  Briefly, 45 female CD-1 mice were 
infected by intraperitoneal injection of 2 x 104 parasites in 100 µL phosphate buffered saline 
glucose (PBS-G).  The animals were divided into three cohorts and assigned to study; the 
neuroinflammatory reaction (n=20), the trypanosome load (n=20) or BBB function (n=5).  
Each cohort was further divided into sub-groups (n=5) to investigate disease progression at 
7, 14, 21 and 28 days post-infection.  Only one group was allocated to MRI as serial scans 
were performed on individual animals at each time point.  Uninfected animals were included 
with the neuroinflammation (n=4) and MRI (n=3) studies to act as normal controls. 
2.2 Histopathology 
The severity of the neuroinflammatory reaction was assessed in groups of mice sacrificed at 
each time-point.  At sacrifice the animals were perfused transcardially with approximately 
120 mL sterile saline.  The brains were then excised, fixed in 4% neutral buffered formalin, 
and paraffin-wax processed.  Coronal sections, taken through the hippocampal brain region, 
were then prepared and stained with haematoxylin and eosin.  The stained sections were 
assessed in a blinded fashion and the severity of the neuroinflammatory reaction graded 
using a previously described grading scale [21].  Briefly, a score of 0 describes a normal 
brain, grade 1 describes sections where a mild meningitis is present while grade 2 shows a 
moderate meningitis with perivascular cuffing of some vessels.  Grade 3 is characterised by 
more severe meningitis and perivascular cuffing with a few inflammatory cells infiltrating the 
neuropil, and grade 4 describes a severe meningoencephalitis with inflammatory cells 
throughout the brain parenchyma. 
2.3 Quantitative PCR 
Trypanosome load in the brain was determined using Taqman real-time PCR as described 
previously [22, 23].  Mice were euthanased at 7, 14, 21 and 28 days -post-infection and 
perfused transcardially with 120 mL of sterile saline to remove peripheral blood from the 
CNS. The brains were then excised, immediately placed in dry ice and stored at -70°C until 
required.  DNA was prepared from a 25 mg sample of whole brain homogenate (DNeasy 
Tissue kit; Qiagen) and Taqman real-time PCR performed [22, 23].  Briefly, Taqman PCR 
  
was carried out in a 25 µL reaction volume comprising 1 x Taqman Brilliant II master mix 
(Agilent), 0.05 pmol/µL forward primer (CCAACCGTGTGTTTCCTCCT), 0.05 pmol/µL reverse primer 
(GAAAAGGTGTCAAACTACTGCCG), 0.1 pmol/µL probe (FAM-CTTGTCTTCTCCTTTTTTGTCTCTTTCCCCCT-
TAMRA) (Eurofins MWG Operon) and 100 ng template DNA.  The primers and probe were 
specifically designed to detect the trypanosome Pfr2 gene.  A standard curve, constructed 
using a serial dilution of pCR®2.1 vector containing 1 x 106 to 1 x 101 copies the cloned Pfr2 
target sequence (Eurofins MWG Operon), was include in each PCR plate.  The amplification 
was performed using a MxPro 3005 (Agilent) with a thermal profile of 95°C for 10 minutes 
followed by 45 cycles of 95°C for 15 seconds, 60°C for 1 minute and 72°C for 1 second.  
The trypanosome load within the brain samples was extrapolated from the standard curve 
using the MxPro qPCR software (Agilent). 
2.4 Contrast enhanced magnetic resonance imaging 
MRI was performed at day 7, 14, 21 and 28 post-infection.  Uninfected mice were also 
examined.  All scans were performed as described previously [20].  Briefly, mice were 
anaesthetised with 1-2% isofluorane delivered in a 70:30 NO2:O2 mixture.  The tail vein was 
cannulated with a 26 gauge x 19 mm cannula to facilitate contrast agent administration 
during MRI scanning (Fig. 1A).  The cannula was secured using super glue and masking 
tape and flushed with heparin to prevent the formation of blood clots.  The animal was then 
placed prone into a mouse cradle and restrained using ear and tooth bars to minimise head 
movement.  Anaesthesia was maintained throughout the procedures and respiration and 
heart rate were observed.  Body temperature was continuously monitored via a rectal 
thermocouple and the animal maintained normothermic by an enclosed warm-water circuit 
(Fig. 1B). 
MRI was performed on a Bruker Biospec 7T/30 cm system equipped with an inserted 
gradient coil (121 mm ID, 400mT/m) and a 72 mm birdcage resonator. A surface coil was 
used for brain imaging.  The scanning protocol consisted of a RARE T1 weighted scan 
[effective TE (echo time) 9 ms, TR (repetition time) 8000 ms, 20 averages, matrix 176x176, 
FOV (field of view) 17.6 x 17.6 mm, 20 contiguous coronal slices of 0.4 mm thickness).  
Following the RARE T1 weighted scan 0.1 mL of a solution containing 50 µL gadolinium-
diethylenetriamine penta-acetic acid (Gd-DPTA Magnevist®; Bayer) and 50 µL of sterile 
water was injected via the tail vein cannula.  Five minutes later the T1 weighted scan was 
repeated. Gd-DTPA cannot readily cross the intact blood brain barrier due to its charge and 
high molecular weight [24].  Extravasation of Gd-DTPA observed within the parenchyma 
demonstrates an impairment of the BBB integrity.  A RARE T2 weighted scan (effective TE 
76ms, TR 5362ms, 25 averages, matrix 176 x 176, FOV 17.6 x 17.6 mm, 20 contiguous 
coronal slices of 0.4 mm thickness) was then performed. On completion of the scan the 
  
animals were allowed to recover from anesthesia and the scanning procedure repeated at 
the next time-point. 
Images were analysed using Image J software (http://rsbweb.nih.gov/ij/).  Contrast 
enhancement maps were generated from the pre- and post-contrast T1 weighted scans 
according to the equation: Enh = (Spost – Spre) ÷ Spre where Spost = post contrast agent signal 
and Spre = pre-contrast agent signal.  Regions of interest (ROIs) were manually defined to 
include the entire brain slice. Percentage signal change maps were generated by multiplying 
Enh by 100 and the mean percentage signal change for each brain slice calculated. 
2.5 Statistical analysis 
Data were analysed using analysis of variance methods in Minitab (Minitab inc.). To identify 
significant differences between groups the General Linear Model (GLM) procedure, followed 
by Tukey’s multiple pair-wise comparison tests were applied.  P values of less than 5% were 
considered statistically significant.  Where appropriate data were log transformed prior to 
analysis. Group means were plotted to show means and their standard errors, and the size 
of treatment effects were estimated using differences between group means and their 95% 
confidence intervals.  
3 Results 
3.1 Histopathology 
Although a few inflammatory cells infiltrating the meninges were detected in some of the 
mice as early as day 7 after infection (Fig. 2A) the mean neuropathology score [mean + SE 
(0.400 + 0.245)] for this group of mice was not significantly different [p=0.382, 95% CI for the 
difference in mean score (95% CI) = -0.254, 1.054] to the uninfected group (0.00 + 0.00).  
However, a progressive increase in the severity of the neuroinflammatory reaction was seen 
in the mice as the disease developed (Fig. 3A) and by 14 days -post-infection the 
neuroinflammatory reaction, characterised by the presence of a mild meningitis (Fig. 2B) 
(0.800 + 0.122), was significantly (p=0.012, 95% CI=0.146, 1.454) higher than in uninfected 
mice (Fig. 3A).  A further significant increase (p<0.05) in the severity of the 
neuropathological response was found in mice killed at days 21 (1.500 + 0.158) and 28 
(2.000 + 0.000) post-infection compared to earlier time points (Fig. 3A).  In both of these 
groups the main features of the neuroinflammatory reaction were the presence of moderate 
inflammatory cell infiltration of the meninges and the perivascular space surround some of 
the blood vessels. The presence of perivascular cuffs was most often associated with the 
vessels situated in the hippocampal fissure (Fig. 2C,D).  Summary statistics for the 
neuroinflammatory score data are detailed in supplementary table 1.    
  
3.2 Quantitative PCR 
Trypanosome DNA was detected in the brains of animals killed at day 7 post-infection (155.5 
+ 88.7) (Fig. 3B).  By day 14 post-infection the detectable parasite burden had increased 
significantly (841 + 192; p=0.005) compared to the earlier time-point (Fig. 3B).  The 
trypanosome load seen in the brains of animals killed at 21 days -post-infection showed a 
further rise (2332 + 770).  Although this was an increase of approximately 175% the burden 
was not significantly (p=0.454) higher than that seen in animals on day 14 post-infection.  A 
further rise in the number of parasites residing in the CNS was observed at day 28 post-
infection (6766 + 1607).  The trypanosome load within the brain at this time-point was 
significantly higher than the levels detected at both 7 days -post-infection (p<0.001) and14 
days -post-infection (p=0.010) but failed to reach significance when compared to animals 
killed on day 21 post-infection (p=0.175).  Summary statistics for the trypanosome load 
measured at each time-point are detailed in supplementary table 2 
3.3 Contrast-enhanced MRI 
Successful scans were obtained from at least two animals at each time-point, details of 
completed scans are given in Figure 4A.  It was not always possible to complete a MRI scan 
on each mouse at every time-point.  Failures were encountered due to the technically 
demanding nature of the technique.  In some instances cannulation of the tail vein proved 
impossible or the cannula became dislodged, while on other occasions the indwelling 
cannula became obstructed, most likely due to the presence of a blood clot, and prevented 
injection of the contrast agent.   
The base-line level of signal enhancement present in normal mice following administration of 
Gd-DPTA was determined in uninfected animals.  The mean percentage signal change 
measured in these mice was 7.105 + 0.162% (Figs. 4B and 5).  A similar level of 
enhancement was seen in animals scanned at 7 days -post-infection (7.6 + 0.397%).  
However by day 14 post-infection the mean percentage signal change (15.269 + 0.586%) 
had risen significantly compared to uninfected mice (p<0.001, CI=5.21, 10.93) and mice 
scanned at 7days -post-infection (p<0.001, CI=5.179, 9.992).  At this point the most 
prominent areas of signal enhancement were found in the ventricular and hypothalamic 
areas although more subtle changes could be seen throughout the parenchyma (Fig. 5).  A 
significant (p<0.001, CI=6.881, 11.476) increase in barrier dysfunction of approximately 9% 
when compared to 14 days -post-infection was detected on day 21 post-infection (24.447 + 
0.968%).  A further stepwise rise was apparent in animals scanned on day 28 post-infection 
(28.056 + 0.766%). The mean percentage signal change measured at day 28 post-infection 
was significantly higher (p<0.005) than in all earlier time-points (Fig.4B).  Although the 
  
ventricular and hypothalamic regions exhibited the highest level of contrast infiltration, 
increased signal change was also evident in the striatum, cerebral cortex, thalamus, and 
pons (Fig. 5).  Diffuse BBB impairment was therefore present throughout the brain 
parenchyma and not confined to specific regions, such as the circumventricular organs and 
ventricles, where barrier function is intrinsically weaker.  Summary statistics for the 
percentage signal enhancement data are detailed in supplementary table 3.    
4 Discussion 
The GVR 35 T.b.brucei mouse model is well established and characterised.  In this model 
administration of trypanocidal drugs used to treat stage-1 infections, such as diminazene 
aceturate or suramin, will successfully cure the disease when they are given prior to day 21 
post-infection.  If chemotherapy is delayed beyond this point, only drugs tailored to cure 
stage-2 infections such as melarsoprol will prove effective [23].  Melarsoprol, unlike the 
stage-1 drugs, can cross the BBB to reach therapeutic concentrations within the brain.  This 
information allows us to deduce that mice, infected with T.b.brucei GVR35, have entered 
stage-2 disease, with parasites established within the brain, by 21 days following initial 
infection [21, 25, 26].  The results of the present study indicate the development of 
statistically significant neuroinflammatory reactions, parasite burden and BBB dysfunction in 
animals at 14 days -post-infection, prior to the onset of established CNS-stage disease.  All 
of the criteria investigated increased as the infection progressed through to the CNS-stage 
and demonstrated significantly greater levels on day 28 post-infection compared with day 14 
post-infection.   
The presence of trypanosomes situated in the brain parenchyma has been frequently 
documented in rodent models of HAT during both the chronic [16, 17, 27] and more acute 
stages of the infection [22, 28].  Furthermore, manipulation of the immunological 
microenvironment has been shown to alter the ability of the parasites to enter the neuropil 
and mice deficient in CXCL10 or IFN-γ show reduced parasite numbers in the parenchyma 
or fail to develop CNS-stage infections [29, 30].  In this study, Taqman PCR was used to 
assess the number of trypanosome present within the brain.  This technique is highly 
sensitive and showed that parasite DNA was present at low levels as early as 7-days after 
infection and found in rising quantities at 14, 21 and 28 days -post-infection.  Taqman PCR 
does not provide details regarding the location of the parasites within the brain tissue.  It is 
possible that small quantities of blood, remaining in the blood-vessels following perfusion, 
could be responsible for the low numbers of trypanosomes identified during the early stage 
of the infection.  At later time-points a more substantial parasite burden was detected.  
However, since we have no information regarding the location of the parasites, it could be 
argued that they may not be present in the brain parenchyma but situated in the meninges, 
  
ventricles or other areas such as the circumventricular organs where the blood-vessel 
epithelium is fenestrated.  In fact, recent investigations in a rat model of infection, using 
freeze fracture electron microscopy, suggested that trypanosomes do not reside in the 
neuropil of the brain, until the terminal stages of the infection, but persist between the cell 
layers in the pia mater where the population size is controlled by prostaglandin-D2 [31].  The 
increasing brain parasite burden detected here argues against this scenario in this study; 
and since no cyclical fluctuations in the trypanosome population were apparent this would 
suggest that the parasites were not situated in the choroid plexus, or CSF [31, 32].  The 
presence of high levels of residual DNA from dead or dying parasites also seems unlikely 
due to the high turnover of CSF in the brain [33-35]. 
The apparent inception of neurological involvement during early-stage infections has been 
identified previously in animal models of trypanosomiasis.  The presence of trypanosomes 
within the CNS, only hours following infection, was demonstrated in a murine model of 
sleeping sickness [28].  Here the authors used intravital microscopy to show fluorescently 
tagged T.b.rhodesiense IL1852 and T.b.brucei GVR35 in the cortical microvasculature and 
brain parenchyma 5 hours following intravenous infection.  A recent study by Laperchia et al. 
[22] demonstrated the presence of parasites and T-cells in the brain parenchyma at day 9 
post-infection in a T.b.brucei rat model of HAT.  The authors present confocal images 
illustrating parasite traversal of the blood vessel endothelia to enter the neuropil on day 9 
post-infection and show high parasite burdens by day 21 post-infection.  In addition, this 
study detected the occurrence of sleep-onset rapid eye movement (SOREM) episodes in the 
rats during the first week following infection and demonstrated that the number and duration 
of these episodes did not correlate with the trypanosome load found in the brain 
parenchyma.  SOREM periods represent a disruption of the normal sleep architecture and 
are typically thought to be associated with CNS-stage infections [36].  However, in the 
Laperchia study they became apparent early after infection demonstrating the presence of 
neurological features associated with early-stage disease.  In human cases of sleeping 
sickness, caused by T.b.rhodesiense, a similar disconnect between the incidence of 
neurological signs, and development of stage-2 infection occurs [37].  Patients presenting 
with either early and late-stage infections exhibited symptoms such as altered gait, tremors, 
incontinence, crania nerve palsy, somnolence and reduced Glasgow coma score.  Indicating 
that these neurological signs can occur prior to progression to stage-2 disease.   
The few reports detailing the neuropathological features in post-mortem samples from fatal 
cases of HAT describe the development of a diffuse meningoencephalitis, with the 
inflammatory infiltrate comprised of macrophages, lymphocytes and plasma cells [5, 6, 38].  
Astrocyte and microglial cell activation was also noted.  The neuroinflammatory changes 
  
were most apparent in the white matter of the cerebral hemispheres but also occurred in the 
circumventricular areas.  The neuroinflammatory picture has also been described in rodent 
[9, 16, 27, 29, 39-43] and primate [7, 44-46] models of trypanosome infection.  Although 
these studies reported a similar response to that described in human cases the development 
of a meningoencephalitis, with inflammatory cells infiltrating the brain parenchyma, was only 
seen on a few occasions and was more commonly associated with treatment failures [7, 45, 
47].  In the T.b.brucei murine model used in this study only mild to moderate 
neuroinflammation, with inflammatory cells present in the meninges and infiltrating the 
perivascular space in the later stages of the infection, was found corresponding with the 
reaction previously reported in the alternative animal models.   
Contrast-enhanced MRI has been used previously to demonstrate BBB dysfunction during 
stage-2 infections [20].  In the present study these findings have been confirmed and 
extended to examine earlier time-points following infection.  It is now clear that barrier 
impairment becomes apparent during the haemolymphatic stage of the infection since a 
significant enhancement in signal intensity, to a mean of 15.85%, was apparent on day 14 
post-infection compared to uninfected animals and those examined at the earlier time-point.   
The degree of barrier damage was further augmented to 25.41% at 21 days -post-infection 
and 28.82% on day 28 post-infection indicating that the trypanosome infection results in a 
progressive loss of BBB function.  Although the increased signal intensity was most marked 
in the ventricular regions, infiltration of the contrast agent was not confined to these areas 
(Fig. 5) but found throughout the brain slice.  Since signal enhancement was present 
throughout the brain parenchyma it is unlikely that the influx of contrast agent is restricted to 
traversal of the blood-CSF barrier and seems also to occur through the BBB.  In earlier 
studies using an in situ perfusion model, the authors found evidence of BBB impairment, 
assessed by measuring [14C]sucrose concentrations in the parenchyma, during the late-
stage of infection in a BALB/c mouse model [18, 48].  Philip et al. [17] also found evidence of 
BBB dysfunction in a rat model of HAT.  In this case rhodamine dye was injected into the 
jugular vein at specific time-points following infection.  Low levels of dye leakage into the 
brain, at first confined to the thalamus and hypothalamus, were seen at 21 days post-
infection with widespread penetration of both the white and grey matter evident by day 40 
after infection.  Again, this study fails to identify any barrier impairment at the earlier time-
points after infection.  The disparity between the current study and those previously 
published is likely a result of the differing methodologies used.  MRI uses contemporary 
contrast agents that result in low levels of signal enhancement in the brain even in normal 
animals whereas rhodamine may remain excluded until more overt changes in barrier 
function develop.  A similar situation exists with the use of sucrose as a marker of BBB 
  
permeability since this compound is considered to be excluded from the brain parenchyma 
under normal conditions [49].  Interestingly, BBB dysfunction, assessed using the 
CSF/serum quotient of albumin, were detected in 6% of patients presenting with stage-1 
T.b.rhodesiense infections [37].  This figure increased to 42% when the stage-2 cases were 
examined indicating the development of progressive BBB impairment with advancing 
disease. 
This results of this study highlight the apparent inconsistency between the trypanosome 
burden in the brain and the degree of BBB impairment as evidenced by the severity of the 
neuroinflammatory reaction present within the brain of trypanosome infected animals.  
Although statistical differences between the neuropathology scores were apparent between 
the groups of mice examined through the various stages of disease progression the 
neuroinflammatory response remained mild to moderate throughout with no inflammatory 
cells infiltrating the neuropil.  This suggests that the mechanisms in place within the brain to 
control the inflammatory response and maintain homeostasis remain largely effective despite 
the barrier dysfunction and the increasing parasite burden.  Furthermore, the 
neuroanatomical expression patterns of tight junction proteins and adhesion molecules differ 
between the BBB, the blood-meningeal barrier and the blood-CSF barrier [50].  This could 
result in differential infiltration of specific regions dependent on the particular immune 
environment.  Several host and parasite factors have been implicated as key determinants of 
disease progression.  These include molecules regulating both the innate and adaptive 
immune response.  For example, Toll-like receptor (TLR) 2- and TLR9- MyD88 signalling 
have been shown to stimulate the expression of inflammatory mediators such as TNF-α and 
IFN α/β which initiate leucocyte and parasite transmigration into the CNS [51] and additional 
inflammatory mediators such as IFN-γ [29, 51] and CXCL10 [51] have also been shown to 
play a vital role in this process.  Furthermore, the migration of leucocytes across the BBB as 
well as the laminin subtype composition of the basement membrane, influence the ability of 
trypanosomes to enter the CNS [29, 42] and increased levels of ICAM and E-selectin have 
been demonstrated following infection [42].  Other non-immune molecules such as matrix 
metalloproteases [42], and parasite cysteine proteases [52] also appear to affect BBB 
penetration by the parasites.   
The ability to stage human infection accurately has become a focus of attention in recent 
years.  The current WHO guidelines suggest that the presence of more than five white blood 
cells / µL of CSF or the presence of trypanosomes indicates that the infection has entered 
stage-2 [1].  Nevertheless, WHO recognise that many of the patients presenting with 
between six and 20 white blood cells / µL are likely to be in an intermediated stage, prior to 
the onset of stage-2 disease [1].  Precise disease staging is pivotal in determining the 
  
correct chemotherapeutic approach for optimal therapy.  Treatment of stage-2 infections with 
suramin or pentamidine will fail to cure the infection resulting in relapse or exacerbation of 
the neuroinflammatory reaction while unnecessary use of toxic stage-2 drugs, such as 
melarsoprol, should be avoided due to the high incidence of extremely severe adverse 
reactions [4, 53].  The results reported here show that BBB dysfunction and 
neuroinflammation manifest before the onset of stage-2 infections.  In addition, parasite DNA 
can be detected in the brain tissue early after infection.  These findings challenge the 
prevailing notion that parasites simply cross the BBB to enter the CNS and initiate 
inflammation during the transition from acute to CNS-stage disease, and also highlight the 
need for further research into the neuropathogenesis of trypanosomiasis.  In addition the 
results reported here question the value of the criteria currently employed to defining stage-1 
and stage-2 HAT and highlight a requirement to elucidate accurate markers of stage-2 
infection to facilitate the development of improved, accurate diseases staging tools.   
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Figure 1.  Preparation of mouse prior to contrast enhanced magnetic resonance 
imaging.  A. The mouse was anaesthetised (blue arrow) and the tail vein cannulated (black 
arrow) to allow administration of contrast agent.  Electrodes were placed on the thorax and 
abdomen to monitor respiration and heart rate (red arrow).  B. The animal was the 
transferred into the MRI cradle and the head restrained with ear (*) and tooth bars to prevent 
movement during the scan.  A rectal thermocouple was used to monitor body temperature 
(blue wire) and which was maintained by an enclosed water circuit (yellow arrow) which 
surrounded the mouse.   
 
Figure 2.  The neuroinflammatory reaction.  Coronal brain sections, prepared at the level 
of the hippocampus, and stained with haematoxylin and eosin were employed to assess the 
neuroinflammatory reaction in uninfected mice (A) and mice infected with T.b.brucei.  
Inflammatory cells can be seen infiltrating the meninges (blue arrows) of the cerebral cortex 
on day 14 post-infection (B) and are most abundant at day 21 (C) and 28 (D) post-infection.  
Inserts show the development of mild perivascular cuffing of the vessels in the hippocampal 
fissure (black arrows) on days 21 (C) and 28 (D) post-infection.  (magnification; x200, 
calibration bar (20 µm) shown in panel D) 
 
Figure 3.  Assessing the neuroinflammatory response and brain parasite burden.  A. 
The neuroinflammatory response scores were analysed in uninfected animals (n=4) and 
animals killed at 7, 14, 21 and 28 days post-infection (n=5 per group).  An increase in the 
severity of the reaction can be seen as the infection progresses.  B. The number of copies of 
the parasite specific PFR-2 gene in a 100ng sample of DNA extracted from the brains 
animals killed at 7, 14, 21 and 28 days post-infection (n=5 per group) was measured by 
Taqman PCR.  The trypanosome burden within the CNS increases as the disease 
progresses with a significant increase in parasite load detected at 14 days post-infection 
compared to the earlier time-point.  A and B. Dots represent the group mean, bars represent 
one standard error of the mean.  The means of groups that do not share a letter are 
significantly different (p<0.05) from each other.   
Figure 4.  Assessing BBB dysfunction.  A. Summary table indicating successful scans () 
performed at each stage after infection.  B.  The degree of BBB dysfunction was determined 
by calculating the percentage signal change present in the brain following CE-MRI.  
Significant levels of barrier impairment were detected on day 14 post-infection compared 
with uninfected animals or those scanned at 7 days post-infection.  A stepwise increase in 
BBB dysfunction was detected at days 21 and 28 post-infection.  Dots represent the group 
  
mean (n=2-4 in each group), bars represent one standard error of the mean. The means of 
groups that do not share a letter are significantly different (p<0.05) from each other. 
 
Figure 5.  MRI percentage signal change maps.    Percentage signal change maps 
(coloured), together with their respective T2 weighted scan images (grey), from an individual 
mouse, at each time-point studied are provided.  In each case three slices, from the 20 
measured in the procedure, are shown.  The slices illustrated have been taken at similar 
levels in each mouse and cover the range of the scan.  The colour bar represents the 
percentage signal change, with brighter colours corresponding to higher levels of change 
and therefore more severe BBB dysfunction.  An increase in the intensity of the colours 
within the signal change maps can be clearly seen from day 14 post-infection and is most 
apparent in animals scanned on day 28 post-infection.  Brain structures relevant to the 
images shown are described.  LV, lateral ventricle; CTX, cerebral cortex; cing, cingulum; Str, 
striatum; aco,`anterior commissure; ACB, nucleus accumbens; CP, Caudate putamen; V3, 
third ventricle; cc, corpus callosum; HPF, hippocampal formation; HY, hypothalamus; int, 
internal capsule; SC, superior colliculus; AQ, aqueduct (4th ventricle); pons, pons. 
  
  
Highlights 
• Contrast enhanced – magnetic resonance imaging detected a significant degree of 
BBB impairment in mice at 14 days following trypanosome infection, which increased 
in a step-wise fashion as the disease progressed in the GVR35 Trypanosoma brucei 
brucei murine model of HAT. 
• Parasite DNA was present in the brain tissue on day 7 after infection; the quantity 
detected increased significantly by day 14 post-infection and continued to rise as the 
infection advanced. 
• A progressive increase in neuroinflammation was detected following trypanosome 
infection, reaching a significant level of severity on day 14 post-infection and rising 
further at later time-points. 
• Results indicate that changes in the CNS become apparent prior to the onset of 
established stage-2 disease. 
 
 
